EyePoint Pharmaceuticals has been granted a patent for compositions containing multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. The patent also covers methods for treating angiogenesis-related conditions by administering these compounds. Additionally, a method for treating ocular conditions using antibodies activating Tie2 and inhibiting VEGF function has been claimed. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of February 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of ocular conditions using multi-specific compounds
A recently granted patent (Publication Number: US11873334B2) discloses a method for treating various ocular conditions in a subject by administering a specific antibody. The antibody comprises a first domain that activates Tie2 and a second domain that binds to and inhibits the function of VEGF. This method is particularly useful for treating conditions such as diabetic retinopathy, neovascularization, vascular leak, increased intraocular pressure, ocular edema, diabetic macular edema, wet age-related macular degeneration, ocular inflammation, and retinal vein occlusion.
The method allows for the administration of the antibody through various routes such as intravitreal, subcutaneous, or systemic, with the therapeutically effective amount ranging from 0.25 mg to 200 mg. Additionally, the patent specifies dosages ranging from 1 mg/kg to 10 mg/kg or from 1 mg to 50 mg, depending on the specific ocular condition being treated. The patent emphasizes the potential of this method in providing targeted treatment for a range of ocular conditions in human subjects.
To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
